Several TC-HR proteins including TRDMT1 are commonly upregulated in breast and ovarian tumors, regardless of the BRCA status, and contribute to PARPi resistance in cancer cells6,29, suggesting TRDMT1 as a promising therapeutic target for cancer treatment. Here, TRDMT1 is linked to ovarian neoplasm.